Abstract:Background: CD147 plays a pivotal in the process of many malignancies. It remains unclear whether CD147 expression has clinical significance with cervical lesions. The current research was aimed to assess the expression of CD147 and investigate its relevance with the tumorigenesis and clinicopathological progression of cervical cancer. Materials and methods: Immunohistochemistry was conducted to evaluate the expression of CD147 within a total of 494 cases of cervical lesions, which were composed of chronic cervicitis (n=54), condyloma acuminatum (CA, n=42), carcinoma in situ (CIS, n=38), adenocarcinoma (n=63), squamous cell carcinoma (SCC, n=263) and adenosquamous carcinoma (n=34). SPSS 22.0 was used to analyze the relationship of CD147 expression and clinicopathological features of cervical lesions. CBioPortal was used to assess the OncoPrint of CD147 based on the data from The Cancer Genome Atlas (TCGA), and the prognostic value of CD147 in cervical cancer was shown by Oncolnc. Results: CD147 expression showed a positive rate of 22.2%, 31.0%, 42.1%, 55.6%, 66.5% and 64.7% from chronic cervicitis, CA, CIS to adenocarcinoma, SCC and adenosquamous carcinoma, respectively. CD147 expression level was statistically higher in cancer than non-cancerous tissues (P<0.001). Results from Spearman correlation test confirmed that CD147 had positive correlation with age, lymph node metastasis, FIGO stage, TNM stage, as well as pathological grade (all P<0.05) in adenocarcinoma. As for SCC, CD147 was positively related to lymph node metastasis, FIGO stage, TNM stage and pathological grade (all P<0.001). In adenosquamous carcinoma, a positive correlation was observed between CD147 and lymph node metastasis, FIGO stage and TNM stage (all P<0.05). Furthermore, Gene alteration of 79 among 307 cases (26%) was shown by CBioPortal based on RNA-seq data. Conclusions: CD147 may have a significant effect on the tumorigenesis and progression of cervical cancer, and it is anticipated to be a potential diagnostic and therapeutic biomarker.

Expression of CD147 in Human Glioma and Its Clinical Significance

Prognostic significance of CD147 in patients with glioblastoma

The Expression of CD44s and Mib-1 in Astrocytomas and Their Clinical Significance

[Expression and Clinical Significance of HAb18G/CD147 in Malignant Tumors].

Specific expression of CD147 in prostate cancer tissues

Expression of CD147 in Advanced Non-Small Cell Lung Cancer Correlated with Cisplatin-Based Chemotherapy Resistance.

Over-expressed CD 147 may be a reminder of tumor progression in cervical lesions : an immunohistochemical investigation with 494 cases

Expression of CD147 Protein in Human Cervical Carcinoma

CD147 Expression in Pituitary Adenomas and Its Significance for Clinical Outcome

Expression of CD133 in different grade gliomas and its clinical significance

The expression and clinical significance of CD147 in testicular tumor

Expression of CD147 is Associated with Prostate Cancer Progression

[Expression and Significance of CD147 Protein in Prostate Cancer].

CD147 Expression Indicates Unfavourable Prognosis in Prostate Cancer

The Roles of CD147 in the Progression of Gliomas

Expression of CD147, PCNA, VEGF, MMPs and Their Clinical Significance in the Giant Cell Tumor of Bones.

Expression of CD147 As a Significantly Unfavorable Prognostic Factor in Hepatocellular Carcinoma

Role of CD147 in glioblastoma progression and the inhibitory effect of its antiseuse RNA on tumor invasion and angiogenesis

[Highly Expressed CD147 on CD4⁺ Tumor Infiltrating Lymphocytes Promotes the Progress of Breast Cancer].

Expression of extracellular matrix metalloproteinase inducer CD147 and MMP-9 in hepatocellular carcinoma and its clinical significance

Expression of CD147 and Matrix Metalloproteinase-11 in Colorectal Cancer and Their Relationship to Clinicopathological Features.